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'p < 0.05, t P < 0.005
We conclude, MVr causes a more rapid and complete restitution of LVEF,
FS, ESS and contractility (ESS/ESVi) to preop level than MVR, while RVEF
improves rapidly after either.
Echocardiographic Assessment of 148 Young
Surviving Patients with Mitral Valve Repair for
Rheumatic Mitral Regurgitation: Long-term
Observations
Aortic Valve Replacement in Patients with Aortic
Stenosis and Low Transvalvular Gradient
Heidi M. Connolly, Jae K. Oh, Veronique L. Roger, Thomas A. Orszulak, Sara
L. Osborn, David O. Hodge, A. Jamll Tajik. Mavo Clinic, Rochester, MN
It has been suggested that patients (pts) with aortic stenosis (AS), LV dys-
function, and mean gradient (MG) <30 mmHg, do not benefit from aortic
valve replacement (AVR) and hence should not be offered surgery. Since
prognosis without operation is dismal, we reviewed our experience and de-
scribe the outcome of 29 consecutive pts with MG <30 mmHg and EF ;S35%
who underwent AVR between 1985 and 1992; (20 M:9 F, mean age 70 ± 12
yrs). Ninety percent (26/29) of pts were severely symptomatic (NYHA Class
III or IV).
Preoperative hemodynamics demonstrated the following mean values: EF
24 ± 7%, MG 23 ± 4 mmHg, aortic valve area 0.7 ± 0.2 cm2, cardiac output
3.4 ± 1.1 L/min, and peak Doppler aortic velocity 3.3 ± 04 m/sec. Coronary
artery disease (CAD) 1::2 vessel CAD or left main) was present in 16 pts
(55%), 13/29 (45%) had prior MI (2 prior CABG). Coronary bypass at the time
of AVR was performed in 17 pts.
The in-hospital mortality was 24% (7129). One and 5-yearsurvival was 63%
and 40% respectively, at a median follow-up of 1 yr, (up to 7 yrs). The pres-
ence of substantial CAD was similar among pts who survived or died periop-
eratively Mean age of surgical survivors was 68 ± 13 yrs vs 78 ± 5 yrs for pts
who died in the perioperative period (p = 0.059). Clinical follow-up was avail-
able in 19122 survivors, 15 of whom improved ::1 NYHA Class. Eleven pts
were asymptomatic (NYHA Class I) and 5 were Class II at follow-up. Postop
EF in 19 survivors had improved, mean postop EF 35 ± 14%.
Conclusion: (1) Pts with AS, LV systolic dysfunction and MG < 30 mmHg
represent a high risk subset; (2) these pts have an increased operative mor-
tality (24%); (3) however, EF and symptomatic improvement occurs in the
majority of survivors. Based on this experience we conclude that pts with
AS, reduced LVEF and low MG should not be denied AVR.
dation functional class III or IV In 74 patients (1 0.6%)the surgery represented
a reoperation. There were 188 126.9%) isolated aortic valve replacements,
109 (15.6%) iSOlated mitral valve replacements, and 403 (57.6%) combined
procedures which included the replacement of at least one valve. There were
42 (6.0%) double valve replacements in the series. Surgery was performed
as an emergency in 42 patients (6.0%). Hospital mortality was 10.1 % Pl pa-
tients) with 629 hospital survivors. There were 661 valves at risk. Follow-up
extended from one month to 15.4 years with a mean of 48.1 months. The
cumulative follow-up was 2,518.7 patient-years. A total of six valves failed
from structural deterioration, one in the aortic and five in the mitral site lp
< 0.004). Actuarial freedom from valve structural deterioration at six years
was 99.0 ± 0.5% standard error of the mean (SEM; 180 valves at risk) and
93.0 ± 3.5% SEM (eight valves at risk) at 12 years. Gender did not influence
structural deterioration; however, valve site did lp < 0.0041. The results of this
large and long-term experience reinforces the continued use of this device in
elderly patients. The paucity of valve failures and a demonstrated enhanced
quality of life experienced by hospital survivors provides further evidence
for the use of the Carpentier-Edwards bioprosthesis in elderly patients with
acquired valvular heart disease.
John Skoularigis, Vania Sinovich, Pinhas Sareli. Baragwanath Hospital,
Johannesburg, South Africa
Detailed echocardiographic assessment of the structural and functional sta-
tus of mitral (M) valve (V) post MV repair for rheumatic M regurgitation (R)
has not been done previously We followed-up (mean 5 ± 3 years, range
0.1-11) 254 patients with MV repair (72% pure M Rand 28% with associ-
ated mild commissural fusion (MCFI, mean age 18 ± 9 years) and report on
the echo-Doppler findings in 148 survivors without reoperation. Anterior M
leaflet prolapse was present in 37% and retraction in 38%. Severe leaflet
thickening was present in 60% and calcification in 50%. Other findings ac-
cording to initial MV lesion:
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Ventricular Size and Function Early and Late After
Mitral Valve Repair vs Mitral Valve Replacement
for Mitral Regurgitation
The Appropriate Choice of a Cardiac Valve
Prosthesis in Elderly Patients
MV-Replacement In = 11) MV-Repair In = 7)
preop early po late po preop early po late po
LVEFre (%) 50 t 42 NS 44 52 NS 51 NS 53
LVEFex (%) 48 NS 44 NS 48 50 NS 49 NS 55
RVEFre (%) 36 ' 43 NS 45 39 ' 48 NS 50
RVEFex (%) 34' 44 ' 48 30 NS 46 NS 49
LVIDd (cm) 6.2 ' 5.4 NS 5.8 7.3 ' 5.4 NS 5.3
FS(%} 33 t 22 NS 25 34 NS 27 NS 28
ESS 80 t 118 NS 109 86 NS 74 NS 81
ESS/ESVi 2.1 NS 2.1 NS 2.1 1.5 ' 2.0 NS 23
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Detlel Wencker, Jeffrey S. Borer, Clare Hochreiter, Phyllis Supino, Richard
B. Devereux, Mary J. Roman, Paul Kliglield. Cornell Medical Center. New York, NY
Late postop course of left and right ventricular (LV, RV) size and function af-
ter surgical relief of mitral regurgitation (MR) is incompletely defined. More-
over, differences following mitral valve repair (MVr) vs replacement (MVRI
have not been fully assessed. Therefore, in 28 pts who had MVR or MVr we
determined rest (re) and exercise (ex) ejection fraction IRVEF, LVEF), dias-
tolic and systolic LV dimensions (IDd and IDs, n ~ 27), fractional shortening
(FS). LV endsystolic stress (ESS, n ~ 25) and contractility (ESS/ESVi, n = 25)
preop and 4-7 yrs postop Ipo): RVEF (re: 37% to 47%; ex: 33% to 47%) and
ESS/ESVi 12.1 to 2.5) improved and LVIDd (6.4 cm to 5.5 cm) and FS 136%
to 28%) decreased (all p < 0.01) while LVEF (re: 52% to 51 %; ex: 51% to
55%). and ESS (84 kdyn/cm2 to 95 kdyn/cm2) were unchanged (all NS). In a
subset of 18 pts (EFre, n ~ 18, ESS/ESVi, n = 15). additional early «1 yr) po
values were obtained:
To determine the accuracy of TEDSE for detection of CAD in women in rela-
tion to other standard non-invasive tests, we studied 49 women lage 51 ± 10
years, range 33-78) who underwent cardiac catheterization, exercise tread-
mill test (ETI) and stress thallium scintigraphy (TI) for evaluation of chest pain
and suspected CAD. Transesophageal echocardiography was performed us-
ing a biplane (13 patients) or an omniplane probe 136 patients), and dobu-
tamine was infused in stepwise increments up to 40 )lg/kg/min. Ten women
had CAD (::70% stenosis of ::1 major coronary artery) and 39 had normal
coronary angiograms. During TEDSE, chest pain developed in 8 of 10(80%)
women with CAD and in 31 of the 39 (79%) with normal coronary arteries (p
~ NSI. Of the 10 women with CAD, 7 had ST segment depression during ETI,
8 had reversible TI defects, and 8 developed new or worsening wall motion
abnormalities during TEDSE (sensitivity: 70%, 80%, and 80%, respectively;
p = NS). Of the 39 women without CAD, 12 had ST segment depression dur-
ing ETT, 8 had reversible Tl defects, and none developed new or worsening
wall motion abnormalities during TEDSE (specificity: 69%,79%, and 100%,
respectively; p < 0.0021. The overall accuracy was 69% for ETT. 80% for TI.
and 96% for TEDSE (p < 0.003). Thus, TEDSE is an accurate test for detec-
tion of CAD among women presenting with chest pain which, by virtue of its
high specificity, compares favorably with other standard methods.
Dennis F. Pupello, Luis N. Bessone, Stephen P. Hiro, Enrique Lopez-Cuenca,
M.S. Glatlerer, Jr., William W. Angell, John C. Brock, Mark J. Alkire, Edward G. Izzo,
G. Sanabria, George Ebra. St. Joseph's Heart Institute, Tampa, FL
The long-term durability of the Carpentier-Edwards bioprosthesis in elderly
patients exceeds 90% at the end of the first decade. This extensive and
long-term experience provides further impetus for the continued use of this
valve substitute with these patients. From October 1977 to June 1994, 700
patients 70 years of age and over underwent valve replacement using a
Carpentier-Edwards porcine bioprosthesis. Ages ranged from 70 to 93 years
with a mean of 75.9 ± 4.2. There were 398 men 156.9%1 and 302 women
143.1 %). Preoperatively, 98.7% of the patients were in New York Heart Asso-
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